Login / Signup

β-Hydroxylation of α-amino-β-hydroxylbutanoyl-glycyluridine catalyzed by a nonheme hydroxylase ensures the maturation of caprazamycin.

Saeid Malek ZadehMei-Hua ChenZhe-Chong WangElahe K AstaniI-Wen LoKuan-Hung LinNing-Shian HsuKamal AdhikariSyue-Yi LyuHsin-Ying TsaiYuma TerasawaMiyuki YabeKazuki YamamotoSatoshi IchikawaTsung-Lin Li
Published in: Communications chemistry (2022)
Caprazamycin is a nucleoside antibiotic that inhibits phospho-N-acetylmuramyl-pentapeptide translocase (MraY). The biosynthesis of nucleoside antibiotics has been studied but is still far from completion. The present study characterized enzymes Cpz10, Cpz15, Cpz27, Mur17, Mur23 out of caprazamycin/muraymycin biosynthetic gene cluster, particularly the nonheme αKG-dependent enzyme Cpz10. Cpz15 is a β-hydroxylase converting uridine mono-phosphate to uridine 5' aldehyde, then incorporating with threonine by Mur17 (Cpz14) to form 5'-C-glycyluridine. Cpz10 hydroxylates synthetic 11 to 12 in vitro. Major product 13 derived from mutant Δcpz10 is phosphorylated by Cpz27. β-Hydroxylation of 11 by Cpz10 permits the maturation of caprazamycin, but decarboxylation of 11 by Mur23 oriented to muraymycin formation. Cpz10 recruits two iron atoms to activate dioxygen with regio-/stereo-specificity and commit electron/charge transfer, respectively. The chemo-physical interrogations should greatly advance our understanding of caprazamycin biosynthesis, which is conducive to pathway/protein engineering for developing more effective nucleoside antibiotics.
Keyphrases
  • mental health
  • dna methylation
  • gene expression
  • drug delivery
  • photodynamic therapy
  • small molecule
  • radiation therapy
  • genome wide
  • cancer therapy
  • binding protein
  • ionic liquid